#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #LOTIS-7

ADC Therapeutics Presents ZYNLONTA Findings at ASH 2026

ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has announced significant new findings from its ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program at the 68th American Society of Hematology (ASH) Annual Meeting, scheduled for December 12–15, 2026, in New Orleans, Louisiana. The data presented encapsulates a robust clinical efficacy narrative for ZYNLONTA across various B-cell malignancies, demonstrating its steadfast commitment to improving patient outcomes.

Key Highlights of the Presentation

The data will be highlighted across five oral presentations and several posters, showcasing the extensive clinical program surrounding ZYNLONTA. Key presentations include:

1. LOTIS-7 Study: This Phase 1b study evaluated the efficacy and safety of ZYNLONTA in conjunction with glofitamab (COLUMVI®) in patients with relapsed or refractory large B-cell lymphoma (r/r DLBCL). Preliminary data indicate an impressive overall response rate (ORR) of 88.7% and a complete response rate (CRR) of 75.3% among 97 efficacy-evaluable patients. Notably, for patients who had previously undergone CAR-T therapy, the ORR stood at 74.1%.

2. Marginal Zone Lymphoma (MZL): A Phase 2 investigator-initiated study revealed a 93% ORR and 74.4% CRR with ZYNLONTA monotherapy for relapsed or refractory MZL, reinforcing the drug's efficacy in hard-to-treat cohorts.

3. LOTIS-5 Study: Full results were unveiled from this Phase 3 study comparing ZYNLONTA plus rituximab against R-GemOx in r/r DLBCL patients, showing a statistically significant median progression-free survival (PFS) improvement of 6.14 months for ZYNLONTA compared to 4.73 months for R-GemOx, along with superior ORR and CRR rates.

Noteworthy Comments from Leadership

Dr. Mohamed Zaki, Chief Medical Officer at ADC Therapeutics, expressed confidence in the breadth and depth of the clinical program, highlighting the compelling nature of the LOTIS-7 and MZL findings which showcase sustained efficacy with manageable safety profiles.

CEO Ameet Mallik remarked on the promising implications these results possess for ZYNLONTA in both clinical and regulatory contexts. He emphasized their ongoing commitment to engage the hematology community at ASH, setting the stage for further developments towards Phase 3 studies and potential new therapeutic roles for ZYNLONTA in treating B-cell malignancies.

Insights into Oral Presentations

Listing of Oral Presentations:

• - Abstract #238: Analysis from the Phase II Column Trial demonstrating the efficacy of Loncastuximab Tesirine in BTK-inhibitor exposed patients.
• - Abstract #619: Updated results from LOTIS-7 focusing on the combination of ZYNLONTA and glofitamab, scheduled for December 13.
• - Abstract #783: Phase II WM-NET1 Trial studying ZYNLONTA in high-risk Waldenström macroglobulinemia, set for December 14.
• - Abstract #784: Multicenter Phase II study on fixed-duration ZYNLONTA in MZL, also on December 14.
• - Abstract #920: Results from LOTIS-5 comparing ZYNLONTA with R-GemOx in DLBCL, on December 14 as well.

Conclusion

The promising data shared at ASH 2026 reaffirms ADC Therapeutics’ dedication to revolutionizing the treatment paradigm for patients with B-cell malignancies through ZYNLONTA. As the company continues to engage with stakeholders, it maintains a trajectory focused on improving patient outcomes while fostering long-term value for its investors. ADC Therapeutics remains optimistic about the future of its clinical programs and the benefits they can bring to patients suffering from challenging hematological conditions.